Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Cost of Revenue (2018 - 2025)

10x Genomics' Cost of Revenue history spans 8 years, with the latest figure at $53.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 2.0% year-over-year to $53.0 million; the TTM value through Dec 2025 reached $198.9 million, up 1.34%, while the annual FY2025 figure was $198.9 million, 1.34% up from the prior year.
  • Cost of Revenue for Q4 2025 was $53.0 million at 10x Genomics, up from $48.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $68.2 million in Q4 2023 and bottomed at $4.9 million in Q2 2021.
  • The 5-year median for Cost of Revenue is $46.2 million (2023), against an average of $40.0 million.
  • The largest annual shift saw Cost of Revenue plummeted 51.1% in 2021 before it skyrocketed 463.66% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $27.6 million in 2021, then skyrocketed by 33.44% to $36.8 million in 2022, then skyrocketed by 85.18% to $68.2 million in 2023, then dropped by 20.72% to $54.1 million in 2024, then decreased by 2.0% to $53.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cost of Revenue are $53.0 million (Q4 2025), $48.7 million (Q3 2025), and $47.8 million (Q2 2025).